Adaptive Biotechnologies signs two TCR licensing deals with Pfizer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. TSCO

Go back to Adaptive Biotechnologies signs two TCR licensing deals with Pfizer

Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer

December 15, 2025 8:00 AM EST

A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis

A data licensing agreement to access Adaptives proprietary TCR-antigen datasets for research and development in multiple immunology applications

SEATTLE, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced two non-exclusive agreements with Pfizer Inc. (NYSE: PFE) to leverage Adaptives proprietary T-cell receptor (TCR) discovery... More